A blood-based screening test that combines prostate-specific antigen with genetic markers and protein biomarkers detected 90 percent of clinically significant prostate cancers in a 12,600-man randomised trial, compared with 74 percent identified by PSA alone, while maintaining a similar false-positive rate. The Stockholm3 study, published in the Annals of Internal Medicine and led by Sweden’s Karolinska Institutet, found that the commonly used PSA threshold of 4 nanograms per millilitre caught only 52 percent of aggressive cases, missing nearly half during initial screening. The test integrates age, family history, and multiple biomarkers to calculate individual risk, and researchers reported it missed one in ten aggressive cancers versus one in four for standard PSA.

A separate international trial presented at the American Society of Clinical Oncology meeting demonstrated that a 50-gene tumour test, Prosigna, can safely identify breast cancer patients who derive no meaningful benefit from chemotherapy. Among more than 4,400 participants across six countries, two-thirds received a low risk score and were treated with hormone therapy alone. After a median follow-up of four years, five-year invasive disease-free survival was approximately 94 percent in both the test-guided and standard-treatment groups, indicating that at most two in every hundred low-risk patients would have a recurrence prevented by chemotherapy.

These findings arrive as clinicians in North America and Europe increasingly emphasise blood-based risk assessment beyond oncology. Cardiothoracic surgeon Jeremy London has highlighted apolipoprotein B and lipoprotein(a) as more precise predictors of heart attack and stroke than standard cholesterol panels. Lipoprotein(a) is genetically determined and largely unresponsive to diet or exercise, a point underscored by a personal account of a Silicon Valley longevity exam that flagged elevated Lp(a) alongside a negative multi-cancer liquid biopsy. The Galleri test used in that exam screens for signals from more than 50 cancers and is particularly sensitive to pancreatic and oesophageal malignancies.

Viewed from Jakarta, the gap between diagnostic innovation and equitable access remains stark. Indonesia recorded over 408,000 new cancer cases in 2022, yet nuclear medicine services reach only ten of its 38 provinces, and radiotherapy is available in 17. Health officials describe an urgent need to expand capacity as the burden of non-communicable diseases rises with an ageing population. The next factual milestones to watch are whether Stockholm3 moves toward regulatory approval and broader clinical adoption, and whether oncology guidelines begin to incorporate gene-expression profiling to de-escalate chemotherapy for a wider range of breast cancer patients, including those with node-positive disease.